Stock NBY NOVABAY PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NovaBay Pharmaceuticals, Inc.

Equities

NBY

US66987P4090

Market Closed - Nyse
Other stock markets
 04:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
2.75 USD -2.48% Intraday chart for NovaBay Pharmaceuticals, Inc. -4.51% -61.48%
May. 09 NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 09 Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
BU
Reverse Split: 1 of 35
FA
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
BU
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
BU
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M
MT
Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
BU
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
BU
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
AQ
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
BU
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
BU
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
BU
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
BU
Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M
MT
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
BU
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBY Stock
  4. News NovaBay Pharmaceuticals, Inc.